Eloira is a novel Levonorgestrel Intrauterine System (LNG-IUS) consisting of 52 mg of levonorgestrel in a cylindrical reservoir on a small polyethylene frame.
Eloira is an extremely safe and effective reversible contraceptive, preventing pregnancy in 99.8% women in first year of use. The contraceptive effect lasts for up to 5 years.
Eloira releases as low as 20 micrograms of LNG per day into the uterine cavity. Therefore it does not have any major systemic side effects.
Additionally Eloira significantly reduces menstrual blood loss and hence will also be suitable for your anaemic clients.
Unlike combined hormonal contraceptives Eloira can be used in the lactation period after six weeks postpartum.
Eloira has an easy Loading and insertion technique. For your convenience, the technique has been included on a Compact Disk present in the pack along with a detailed "Instructions for Use". The pack also contains an information booklet and reminder card for the clients.
Most of the contraceptive effect of the LNG-IUS is mediated via its progestogenic effect on the endometrium. Intrauterine concentrations of LNG are 1000 times higher than with subdermalprogestogen implants. The high intrauterine levels of LNG lead to functional and histological changes within the endometrium which are evident within 1 month of insertion. Endometrial oestrogen and progesterone receptors are down-regulated. There is endometrial atrophy, which is initially patchy, but which becomes more uniform with increasing duration of use. Changes in endometrial stroma occur and there is a marked increase in inflammatory cell number. These complex endometrial effects contribute to the contraceptive efficacy of the LNG-IUS, preventing implantation.
Additionally, the cervical mucus from women using the LNG-IUS reduces net weight (less water content) and is thicker as compared to other IUD users. Sperm penetration decreases when cervical mucus quality is affected by LNG-IUS use. This may contribute to the contraceptive effect for some women.
The LNG-IUS has minimal effect on the hypothalamo-pituitary-ovarian axis. Serum oestradiol levels in most women indicate follicular development. Most women (>75%) will continue to ovulate.